Cargando…
2554. Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine
BACKGROUND: NasoVAX is a replication-deficient adenovirus-based vaccine designed to express influenza hemagglutinin in nasal epithelial cells when given as a nasal spray. In preclinical studies, NasoVAX was associated with divergent strain protection. Prior preclinical and clinical studies with the...
Autores principales: | Tasker, Sybil, Krishnan, Vyjayanthi, Bart, Stephan, Suyundikov, Anvar, Booth, Peta-Gay, Wight O’Rourke, Anna, Zhang, Jianfeng, Georges, Bertrand, Roberts, Scot |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253025/ http://dx.doi.org/10.1093/ofid/ofy209.162 |
Ejemplares similares
-
Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial
por: Tasker, Sybil, et al.
Publicado: (2021) -
Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial
por: Sekuloski, Silvana, et al.
Publicado: (2018) -
2554. A Standardized Medicine Resident Curriculum: Content Survey for an Infectious Diseases Rotation
por: Enriquez, Matthew, et al.
Publicado: (2019) -
2554. What’s Weight Got to Do with It? Prospective Pharmacokinetic/Pharmacodynamic Evaluation of Fixed-Dose Daptomycin
por: Olney, Katie B, et al.
Publicado: (2023) -
HealVax
por: Foerster, John, et al.
Publicado: (2018)